The NET Alliance™ and Novartis Oncology continue their commitment to improving knowledge and management of neuroendocrine tumors, and empowering patients to be more informed advocates.

  • А
  • А
  • А

Multifaceted cancer that benefits from multidisciplinary care

The beauty of the multidisciplinary approach is that each of those [symptoms] gets examined in each case, so that everybody can make a contribution to the management of the patient.

—Dr Rodney Pommier

Because neuroendocrine tumors (NET) are sometimes regarded as being benign or slow-growing, management strategies for patients traditionally have lacked a sense of urgency.1 However, evidence suggests that:

  • NET should be actively monitored because of their progressive nature and poor prognosis with metastatic disease2,3
  • Given their diversity in sites of origin, biology, and symptomatology, NET are optimally managed using therapeutic interventions tailored to the individual patient1
  • Outcomes tend to be better for patients who are treated at NET specialist centers that employ a multidisciplinary approach to patient care4,5

Institutional studies show outcomes are improved for patients who are managed at centers that specialize in NET.4,5

These centers typically employ a multidisciplinary team approach, the potential benefits of which include6:

  • Accurate diagnosis and staging
  • Evaluation of performance status and quality of life
  • Consensus regarding the patient’s care plan
  • Cohesive delivery of support, therapy, and information on prognosis to patients
  • Continuous reassessment, discussion, and peer review of the individualized care plan

Videos of Patients With Neuroendocrine Tumors and Their Stories 

Resource for Nurses: Take the NET Nurse Quiz! 

The NET Nurse Quiz is an interactive quiz to test your knowledge on neuroendocrine tumors and how the disease affects your patients.

Are you ready for the quiz?